Want to see SBFM full AI Analyst Report?
Sunshine Biopharma (SBFM) Stock Statistics & Valuation Metrics
Total Valuation
Sunshine Biopharma has a market cap or net worth of $2.09M. The enterprise value is -$10.19M.
- Market Cap
- $2.09M
- Enterprise Value
- -$10.19M
Share Statistics
Sunshine Biopharma has 760,969 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 760,969
- Owned by Insiders
- 8.98%
- Owned by Institutions
- ―
Financial Efficiency
Sunshine Biopharma’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -18.78%.
- Return on Equity (ROE)
- -0.26
- Return on Assets (ROA)
- -0.20
- Return on Invested Capital (ROIC)
- -18.78%
- Return on Capital Employed (ROCE)
- -0.19
- Revenue Per Employee
- 726.12K
- Profits Per Employee
- -119.51K
- Employee Count
- 50
- Asset Turnover
- 1.21
- Inventory Turnover
- 1.81
Valuation Ratios
The current PE Ratio of Sunshine Biopharma is -0.01. Sunshine Biopharma’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 0.16
- PB Ratio
- 0.01
- Price to FCF
- -1.22
- Price to Operating Cash Flow
- -0.03
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Sunshine Biopharma had revenue of 36.31M and earned -5.98M in profits. Earnings per share was -288.00.
- Revenue
- 36.31M
- Gross Profit
- 11.92M
- Operating Income
- -4.48M
- Pretax Income
- -5.95M
- Net Income
- -5.98M
- EBITDA
- -5.62M
- Earnings Per Share (EPS)
- -288.00
Cash Flow
In the last 12 months, operating cash flow was -5.33M and capital expenditures 736,101, giving a free cash flow of -4.60M billion.
- Operating Cash Flow
- -5.33M
- Free Cash Flow
- -4.60M
- Free Cash Flow per Share
- -67.35
Dividends & Yields
Sunshine Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -77.32%
- Earnings Yield
- -3051.32%
Stock Price Statistics
- Beta
- 1.76
- 52-Week Price Change
- -99.22%
- 50-Day Moving Average
- 13.74
- 200-Day Moving Average
- 103.66
- Relative Strength Index (RSI)
- 26.58
- Average Volume (3m)
- 300.67K
Important Dates
Sunshine Biopharma upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
Sunshine Biopharma as a current ratio of 4.17, with Debt / Equity ratio of 3.53%
- Current Ratio
- 4.17
- Quick Ratio
- 2.08
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 1.48
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Sunshine Biopharma has paid 21.61K in taxes.
- Income Tax
- 21.61K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Sunshine Biopharma EV to EBITDA ratio is 1.35, with an EV/FCF ratio of 1.55.
- EV to Sales
- -0.20
- EV to EBITDA
- 1.35
- EV to Free Cash Flow
- 1.55
- EV to Operating Cash Flow
- 1.34
Balance Sheet
Sunshine Biopharma has $13.75M in cash and marketable securities with $678.34K in debt, giving a net cash position of $13.07M billion.
- Cash & Marketable Securities
- $13.75M
- Total Debt
- $678.34K
- Net Cash
- $13.07M
- Net Cash Per Share
- $17.18
- Tangible Book Value Per Share
- $376.41
Margins
Gross margin is 29.80%, with operating margin of -14.71%, and net profit margin of -16.50%.
- Gross Margin
- 29.80%
- Operating Margin
- -14.71%
- Pretax Margin
- -15.73%
- Net Profit Margin
- -16.50%
- EBITDA Margin
- -14.88%
- EBIT Margin
- -15.87%
Analyst Forecast
The average price target for Sunshine Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.74%
- EPS Growth Forecast
- 60.85%
Scores
- Smart Score
- ―
- AI Score
- 41
